Seeking Alpha

Eli Lilly (LLY -1.1%), Amylin (AMLN -24.7%) and Alkermes (ALKS -14.9%) provide top-line results...

Eli Lilly (LLY -1.1%), Amylin (AMLN -24.7%) and Alkermes (ALKS -14.9%) provide top-line results from a head-to-head study, showing investigational diabetes therapy Bydureon didn't meet the pre-specified primary endpoint of non-inferiority to Victoza (NVO +5%). (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|